Allow yourself about two weeks to judge how the supplements are affecting you, and be sure to keep your fluid and fiber intake at the recommended levels
While recent studies have been promising, the drugs haven't been approved by the Food and Drug Administration (FDA) for this purpose yet
The GLP-1R/GIPR dual-agonist tirzepatide has demonstrated a remarkable 23% body weight reduction in individuals with obesity over 72 weeks, eclipsing the average result achieved by certain bariatric surgery [78]
The decision to prescribe these medications should weigh the substantial metabolic benefits against individual gallbladder risk, recognizing that for most patients, the cardiovascular and glycemic advantages outweigh the relatively modest absolute risk increase
For patients on tirzepatide, which produces a more pronounced caloric deficit due to its dual GIP/GLP-1 mechanism, methylated B12 provides upgraded energy and cognitive support during the weight loss phase
What should you know before considering microdosing
-(1).png?sfvrsn=c236e848_3)
